Medtronic plc [NYSE: MDT] gained 0.82% or 1.02 points to close at $125.17 with a heavy trading volume of 4361754 shares. The company report on June 10, 2021 that Medtronic Announces FDA Approval of its Next Generation Recharge-Free Spinal Cord Stimulation Platform.
Vanta™ Implantable Neurostimulator Offers Up to 11 Year Battery Life and Personalized Pain Relief.
Medtronic plc (NYSE: MDT), the global leader in medical technology, announced it has received U.S. Food and Drug Administration (FDA) approval for Vanta™, a high performance recharge-free implantable neurostimulator (INS) with a device life that can be optimized up to 11 years. At comparable settings, the Vanta neurostimulator offers nearly twice the device life than competitive primary cell devices.1,2 It also utilizes Medtronic’s proprietary AdaptiveStim™ technology for personalized pain relief that adapts to the patient’s movement or body position using a built-in accelerometer. AdaptiveStim technology goes beyond in-office programming by automatically adjusting stimulation to maintain each patient’s optimal dose. The Vanta neurostimulator also provides unmatched full-body MRI access with Medtronic SureScan™ technology.3 Approximately 82% of SCS-implanted patients will need at least one MRI within five years of implant.4.
It opened the trading session at $124.47, the shares rose to $125.3598 and dropped to $123.95, the range by which the price of stock traded the whole day. The daily chart for MDT points out that the company has recorded 11.38% gains over the past six months. However, it is still -42.76% lower than its most recent low trading price.
If we look at the average trading volume of 4.77M shares, MDT reached to a volume of 4361754 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Medtronic plc [MDT]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for MDT shares is $140.12 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on MDT stock is a recommendation set at 1.90. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Cowen have made an estimate for Medtronic plc shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on June 10, 2021. While these analysts kept the previous recommendation, Barclays raised their target price to Equal Weight. The new note on the price target was released on May 25, 2021, representing the official price target for Medtronic plc stock. Previously, the target price had yet another raise to $153, while Atlantic Equities analysts kept a Overweight rating on MDT stock.
The Average True Range (ATR) for Medtronic plc is set at 1.91, with the Price to Sales ratio for MDT stock in the period of the last 12 months amounting to 5.65. The Price to Book ratio for the last quarter was 3.32, with the Price to Cash per share for the same quarter was set at 10.78. Price to Free Cash Flow for MDT in the course of the last twelve months was 97.34 with Quick ratio for the last quarter at 1.70.
Trading performance analysis for MDT stock
Medtronic plc [MDT] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 2.77. With this latest performance, MDT shares dropped by -0.08% in over the last four-week period, additionally plugging by 11.38% over the last 6 months – not to mention a rise of 33.70% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MDT stock in for the last two-week period is set at 50.89, with the RSI for the last a single of trading hit 53.12, and the three-weeks RSI is set at 50.95 for Medtronic plc [MDT]. The present Moving Average for the last 50 days of trading for this stock 125.96, while it was recorded at 124.19 for the last single week of trading, and 115.80 for the last 200 days.
Medtronic plc [MDT]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Medtronic plc [MDT] shares currently have an operating margin of +17.30 and a Gross Margin at +59.27. Medtronic plc’s Net Margin is presently recorded at +11.97.
Return on Total Capital for MDT is now 6.74, given the latest momentum, and Return on Invested Capital for the company is 4.77. Return on Equity for this stock inclined to 7.06, with Return on Assets sitting at 3.92. When it comes to the capital structure of this company, Medtronic plc [MDT] has a Total Debt to Total Equity ratio set at 51.31. Additionally, MDT Total Debt to Total Capital is recorded at 33.91, with Total Debt to Total Assets ending up at 28.35. Long-Term Debt to Equity for the company is recorded at 51.29, with the Long-Term Debt to Total Capital now at 33.90.
Receivables Turnover for the company is 5.96 with a Total Asset Turnover recorded at a value of 0.33.Medtronic plc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.70 and a Current Ratio set at 2.10.
Medtronic plc [MDT]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Medtronic plc posted 0.62/share EPS, while the average EPS was predicted by analysts to be reported at 0.18/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 244.40%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for MDT. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Medtronic plc go to 10.94%.
An analysis of insider ownership at Medtronic plc [MDT]
There are presently around $136,785 million, or 83.70% of MDT stock, in the hands of institutional investors. The top three institutional holders of MDT stocks are: VANGUARD GROUP INC with ownership of 111,062,164, which is approximately -0.201% of the company’s market cap and around 0.10% of the total institutional ownership; BLACKROCK INC., holding 106,754,630 shares of the stock with an approximate value of $13.36 billion in MDT stocks shares; and STATE STREET CORP, currently with $6.85 billion in MDT stock with ownership of nearly -2.174% of the company’s market capitalization.
Positions in Medtronic plc stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 1,009 institutional holders increased their position in Medtronic plc [NYSE:MDT] by around 51,021,082 shares. Additionally, 820 investors decreased positions by around 42,251,360 shares, while 243 investors held positions by with 999,522,531 shares. The mentioned changes placed institutional holdings at 1,092,794,973 shares, according to the latest SEC report filing. MDT stock had 125 new institutional investments in for a total of 3,748,935 shares, while 89 institutional investors sold positions of 2,539,631 shares during the same period.